Forthose who didn't attend AGM, perhaps the 'take home' message from theChairman was that they are focused on commercialisation andincreasing business overseas. They are expecting FDA approval forenteric kit in 2019 and then for other kits to follow. If they cancapture a major US client it will boost revenue greatly.Thedirector from US was at meeting (Mike Aicher). He has been centrally involved in molecular PCR testingfrom way back with large institutes/companies in California. He haslots of experience dealing with FDA and joined GSS because hegenuinely believes the 3-base method is advantageous. As well as being knowledgeable and prominent in the area, he seems like nice guy and personable, so excellent representative for us in US.
Ann: Withdrawal of resolution 4 from 2018 Annual General Meeting, page-6
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
69.0¢ |
Change
0.010(1.47%) |
Mkt cap ! $155.4M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 69.0¢ | 68.5¢ | $145.8K | 211.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2851 | 68.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 70.0¢ | 10137 | 1 |
View Market Depth
| Last trade - 15.46pm 28/11/2024 (20 minute delay) ? |
| GSS (ASX) Chart |
